Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Interactions with Lenacapavir

Tuesday 11 October 2022

Lenacapavir (Sunlenca®) is now included in the list of HIV therapies. Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (CA) subunits. Initiation of treatment with lenacapavir requires tablets to be taken as oral loading prior to administration of a long-acting sub-cutaneous injection which is then administered every 6 months.

Lenacapavir is indicated in the European Union for the treatment of adults with multi-drug resistant HIV infection in combination with other antiretroviral(s), for whom it is otherwise not possible to construct a suppressive anti-viral regimen. A New Drug Application (NDA) has been submitted to the U.S. Food & Drug Administration (FDA) and is currently being considered.

Sponsor logo gilead Sponsor logo viiv Thera logo Frontier logo
Hiv dt glas 2020 cmyk logo Eacs logo 2014 Bhiva 2018 Basel text
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016